GoodRx (NASDAQ:GDRX) Sees Unusually-High Trading Volume – What’s Next?

GoodRx Holdings, Inc. (NASDAQ:GDRX) saw an uptick in trading volume on Monday . 1,694,854 shares were traded during mid-day trading, an increase of 18% from the previous session’s volume of 1,433,816 shares.The stock last traded at $4.34 and had previously closed at $4.15.

Analyst Ratings Changes

Several brokerages recently issued reports on GDRX. Raymond James upgraded GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target for the company in a report on Friday, August 9th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 target price on shares of GoodRx in a research note on Friday, August 16th. UBS Group dropped their price target on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research report on Friday, August 9th. Citigroup reduced their price objective on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Finally, Barclays decreased their price objective on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, GoodRx presently has a consensus rating of “Moderate Buy” and an average target price of $8.86.

GoodRx Trading Up 4.1 %

The firm has a 50 day moving average of $6.55 and a 200 day moving average of $7.42. The firm has a market cap of $1.65 billion, a PE ratio of -138.33, a P/E/G ratio of 3.02 and a beta of 1.39. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70.

Insider Buying and Selling at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 4.17% of the company’s stock.

Institutional Trading of GoodRx

Institutional investors have recently modified their holdings of the business. Rubric Capital Management LP grew its stake in GoodRx by 25.2% in the 3rd quarter. Rubric Capital Management LP now owns 4,680,028 shares of the company’s stock valued at $32,479,000 after buying an additional 943,226 shares in the last quarter. Millennium Management LLC grew its position in shares of GoodRx by 36.5% in the second quarter. Millennium Management LLC now owns 4,121,939 shares of the company’s stock valued at $32,151,000 after purchasing an additional 1,102,758 shares in the last quarter. American Century Companies Inc. purchased a new position in shares of GoodRx in the second quarter valued at $18,183,000. Point72 Asset Management L.P. bought a new stake in shares of GoodRx during the 3rd quarter valued at $11,295,000. Finally, Geode Capital Management LLC lifted its holdings in GoodRx by 6.3% during the 3rd quarter. Geode Capital Management LLC now owns 982,729 shares of the company’s stock worth $6,823,000 after purchasing an additional 58,610 shares in the last quarter. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.